Spectrum Of Activity
HIV-infected patients with no Darunavir resistance associated substitutions 800 mg PO q24h with Ritonavir 100 mg PO q24h
Treatment-experienced HIV-infected patients with ≥1 Darunavir resistance associated substitution 600 mg PO q12h with Ritonavir 100 mg PO q12hNo renal dose adjustment
Safety and efficacy in pediatric patients <3y of age have not been established
HIV-infected pediatric patients with no Darunavir resistance associated substitutions 35 mg/kg PO q24h + Ritonavir 7 mg/kg PO q24h
Treatment-experienced HIV-infected pediatric patients with ≥1 Darunavir resistance associated substitution 20 mg/kg PO q12h + Ritonavir 3 mg/kg PO q12hNo renal dose adjustment
Mild or moderate hepatic impairment No dose adjustment
Severe hepatic impairment No data
Treatment for HIV infection.
Use as part of a 3-drug combination regimen.
Genotypic and phenotypic testing prior to initiation in treatment-experienced patients.
Monitor viral load prior to initiation or modification of ARV treatment at 2-8 weeks.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Serum cholesterol raised
Generalized exanthematous pustulosis
Toxic epidermal necrolysis
Multiple drug-drug interactions
Antimicrobial class: Antiretroviral agent, HIV-1 protease inhibitor
Pregnancy category: C
Average serum half life:15 hours
Urine penetration: Therapeutic
Precautions: Use with caution in patients with hepatic dysfunction and preexisting (e.g. chronic active hepatitis B or C, cirrhosis, elevated transaminases); interruption or discontinuation of treatment may be necessary.
Insulin initiation or dose adjustment, or oral hypoglycemic agents may be required.
Discontinue immediately if skin reactions are suspected.